ACADIA reported a net loss of $5.5 million, or $0.14 per common share, for the first quarter of 2010 compared to a net loss of $15.0 million, or $0.40 per common share, for the first quarter of 2009.
At March 31, 2010, ACADIA's cash, cash equivalents, and investment securities totaled $40.6 million compared to $47.1 million at December 31, 2009. ACADIA continues to expect its existing cash resources and anticipated payments from its collaborations will be sufficient to fund its operations through the end of 2011.
"The beginning of 2010 has been an important period for ACADIA as we and our pimavanserin partner, Biovail, have advanced our preparations for clinical trials of pimavanserin in three separate indications with large unmet medical needs," said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. "We have refined the design of our new Phase III trial in Parkinson's disease psychosis and we remain on track to initiate this study mid-year. We also are continuing to plan for Phase III co-therapy trials in schizophrenia and a Phase II feasibility study for Alzheimer's disease psychosis. We believe this broad development program with pimavanserin, coupled with ACADIA's other product candidates in development, positions us with multiple attractive product and commercial opportunities and significant growth potential."
Revenues increased to $2.1 million for the first quarter of 2010 from $374,000 for the first quarter of 2009. This increase was primarily due to $1.4 million in revenues recognized under ACADIA's collaboration with Biovail, which commenced in May 2009, as well as increased revenues from other agreements.
Research and development expenses decreased to $5.8 million for the first quarter of 2010, including $229,000 in stock-based compensation, from $12.6 million for the first quarter of 2009, including $221,000 in stock-based compensation. This decrease was primarily due to $5.3 million in lower external service costs as well as cost savings from ACADIA's restructuring implemented in October 2009. The decrease in external service costs was primarily attributable to lower clinical costs incurred on ACADIA's Phase III program with pimavanserin for Parkinson's disease psychosis.
General and administrative expenses decreased to $1.8 million for the first quarter of 2010, including $252,000 in stock-based compensation, from $3.0 million for the first quarter of 2009, including $354,000 in stock-based compensation. This decrease was primarily due to lower external service costs and cost savings from ACADIA's restructuring.
Conference Call and Webcast Information
ACADIA management will review its first quarter results and development programs via conference call and webcast later today at 5:00 p.m. Eastern Time. The conference call may be accessed by dialing 866-730-5770 for participants in the U.S. or Canada and 857-350-1594 for international callers (reference passcode 42433083). A telephone replay of the conference call may be accessed through May 24, 2010 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 90954803). The conference call also will be webcast live on ACADIA's website, www.acadia-pharm.com, under the investors section and will be archived there until May 24, 2010.
http://www.finanznachrichten.de/...ter-2010-financial-results-004.htm
-----------
Keine Kauf Empfehlung!!
Wer nicht fähig ist, selber eine Meinung zu bilden und eine Entscheidung zu treffen, darf nicht zur Börse.
|
Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.
Zurück geht es hier.
Thread abonnieren
